<DOC>
	<DOC>NCT01213355</DOC>
	<brief_summary>It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive impairments in healthy adults subjects.</brief_summary>
	<brief_title>Scopolamine Challenge Study</brief_title>
	<detailed_description>Proof of mechanism</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Healthy male and/or female subjects of non child bearing potential (WONCBP) between the ages of 18 and 55 years, inclusive. Body Mass index (BMI) of between 17.5 to 30.5 kg/m2 inclusive; and a total body weight greater than or equal to 50 kg (110 lbs). Presence or history of any disorder that may prevent the successful completion of the study. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Randomized</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>5-way crossover</keyword>
	<keyword>single oral administrations of PF 05212377</keyword>
	<keyword>scopolamine induced deficits in healthy subjects</keyword>
</DOC>